UBS
投资主体（类型未细分）
Verified investment lower bound≥$22.38M
Investment cases2
Manager operating history—
Representative investments
Individual transactions and cumulative snapshots use different bases. Do not add these rows again to cumulative totals.
| Date | Company | Round | Original-currency amount | Paying entity | Specific funds | Sources |
|---|---|---|---|---|---|---|
| 2025-12-30 | Insilico Medicine（英矽智能） | IPO最终获配认购 | HKD 175.52M | UBS Asset Management (Singapore)及O’Connor团队 | — | Sources · 2
Basis and notes基石4,853,000股＋额外国际配售2,445,000股，合计7,298,000股×HK$24.05。按最终配售计算认购款，不含费用，不声称银行流水已核。上市日为交易事件日期，非银行付款日。美元仅使用本站既有汇率快照；不是按当前股价计算。 |